Exeliom Biosciences

Exeliom Biosciences is a clinical-stage biotechnology company based in Dijon, France, founded in 2016.

The company focuses on developing next-generation immunotherapies for immuno-oncology and immuno-inflammation by utilizing microbiome-associated innate immune regulatory mechanisms. Exeliom specializes in creating live biotherapeutic products (LBPs) using single bacterial strains from the gut microbiota to modulate the immune system, with a mission to innovate treatments for inflammatory bowel diseases, cancer, and infectious diseases. The company's lead candidate, EXL01, is an oral live biotherapeutic designed to enhance immune responses by targeting the NOD2-CARD9 pathway. EXL01 is currently in clinical trials for various conditions, including Crohn’s disease, ulcerative colitis, and several types of solid tumors. Exeliom has secured significant funding to advance its clinical development and is actively seeking partnerships and investor support to further its innovative pipeline.